Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LILLY/MYLAN CIMETIDINE CO-PROMOTION AGREEMENT HAS CIMETIDINE AS FIRST-LINE ULCER THERAPY; LILLY's AXID RESERVED FOR GERD AND SECOND-LINE ULCER USE

Executive Summary

Lilly is promoting its H[2] antagonist Axid as a second-line ulcer therapy to generic cimetidine in its disease management marketing to managed care buyers.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS024374

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel